Investor Presentaiton

CSL Today 3rd Largest Global Biotech Global #1 in plasma therapies • $30 billion industry Global #2 in influenza vaccines $1 • $1 • $6 billion industry Strong Market Position • • Revenue FY19 ~$8.5bn 8 major manufacturing sites in 6 countries Major capacity expansion underway Deep R&D pipeline fueling future growth Solid Financial Position • Net debt/EBITDA 1.4x • A3/A- credit rating (stable/stable) Current Industry Themes Plasma Supply Growth Robust lg demand Influenza Vaccine Technology Shift 5 | Driven by Our Promise™ CSL

View entire presentation